Related Experiment Video
Updated: Jul 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Treatment and costs associated with anemic chronic kidney disease patients
Rafia S Rasu1, Tonya Crawford, Harold Manley
1School of Pharmacy, University of Missouri Kansas City, Kansas City, MO 64106, USA. rasur@umkc.edu
Insights
Early detection and treatment of anemia in chronic kidney disease (CKD) patients improve health outcomes. Optimizing therapies like iron and erythropoiesis-stimulating agents (ESAs) is key for managing anemia in CKD.
Area of Science:
- Nephrology
- Hematology
Background:
- Anemia is a common complication in chronic kidney disease (CKD).
- Anemia in CKD negatively impacts cognitive and physical function.
- Effective management of anemia is crucial for CKD patient well-being.
Purpose of the Study:
- To review current therapeutic strategies for anemia in CKD patients.
- To examine the associated costs of these anemia interventions.
Main Methods:
- A literature search was conducted using Ovid MEDLINE.
- Articles published between 1996 and 2007 concerning anemia treatment in CKD were reviewed.
Main Results:
- Early anemia detection and treatment in CKD patients yield positive cognitive and physical benefits.
- Therapies enhancing iron availability and erythropoietin production aid in achieving target hemoglobin levels.
- Awareness of potential medication side effects can prevent further patient injury and reduce healthcare costs.
Conclusions:
- Healthcare providers should proactively detect and manage anemia in CKD.
- Further research is needed on erythropoiesis-stimulating agents (ESAs) in predialysis CKD patients.
- Comparative cost analyses of epoetin and darbepoetin alpha are warranted.
Objective:
The purpose of this paper is to provide an overview of the current therapeutic options afforded to anemic chronic kidney disease (CKD) patients and the costs of these interventions.
Methodology:
Literature search of articles within Ovid MEDLINE between 1996 and 2007 that pertained to the treatment of anemia in chronic kidney disease patients.
Results:
Early detection and treatment of anemia associated with CKD has proven to provide positive cognitive and physical effects. Treatment options that increase iron storage and availability within the body and production of erythropoietin can assist in anemic CKD patients in achieving recommended levels of hemoglobin. Acknowledgement of the potential side effects associated with the medications selected to treat anemia can help in avoiding additional injury to the patient and thus reduce healthcare expenditure. A limitation of this review is that the search was performed within a single database.
Conclusions:
Health care providers can play an active role in detecting anemia early and optimizing available treatment options. Future research on the effects of erythropoiesis-stimulating agents (ESA) on patients before they need dialysis, and a cost analysis between epoetin and darbepoetin alpha, would be beneficial.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention